StockData
Candel Therapeutics, Inc. logo

Candel Therapeutics, Inc. (CADL) stock

CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 1/30
$5.40−0.41 (-7.06%)

Close on Nov 17, 2026Market cap $413.20MP/E –Yield –

Candel Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Candel Therapeutics's operating margin for the twelve months ending Dec 31, 2022 was -27777.6%. For fiscal 2022 it was -27777.6%, against -20580.8% the year before.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2022Dec 31, 2022-27777.6%−7196.8
FY2021Dec 31, 2021-20580.8%−9532.8
FY2020Dec 31, 2020-11048.0%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q4 FY2022Dec 31, 2022-26132.3%−1164.5
Q3 FY2022Sep 30, 2022-28648.4%−2748.4
Q2 FY2022Jun 30, 2022-28235.5%−11135.5
Q1 FY2022Mar 31, 2022-28987.1%−13964.5
Q4 FY2021Dec 31, 2021-24967.7%−5209.7
Q3 FY2021Sep 30, 2021-25900.0%−17032.3
Q2 FY2021Jun 30, 2021-17100.0%−8651.6
Q1 FY2021Mar 31, 2021-15022.6%–
Q4 FY2020Dec 31, 2020-19758.1%–
Q3 FY2020Sep 30, 2020-8867.7%–
Q2 FY2020Jun 30, 2020-8448.4%–

More Candel Therapeutics figures

See a number that looks wrong?